Prices delayed by at least 15 minutes | Print
Puretech Health PLC (PRTC)
ORD 1POpen
112.00p
Previous close
114.60p
Trade high
112.00p
Volume
1
Year high
143.60p
Year low
106.60p
Dividend yield
–
Market capitalisation
£280.98 mn
P/E ratio
10.35
ISIN
GB00BY2Z0H74
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Regular investment and Dividend reinvestment
Share price
Company profile
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, whichderives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 19/10/2026 | 08:00:15 | 112 | 1 | 1.12 |
| 16/10/2026 | 04:35:15 | 114.6 | 832,897 | 954,499.96 |
| 16/10/2026 | 04:29:51 | 113.8 | 917 | 1,043.55 |
| 16/10/2026 | 04:29:51 | 113.8 | 601 | 683.94 |
| 16/10/2026 | 04:29:51 | 113.8 | 760 | 864.88 |